Phaseline

Targets › DUX4

DUX4 (Double homeobox protein 4): drug programs, companies and trials

2 programs from 1 company in 2 trials: 1 Phase 3, 1 Phase 2; Neurology, Immunology; next expected readout May 2028.

[Isoform 1]: Transcription factor that is selectively and transiently expressed in cleavage-stage embryos. Binds to double-stranded DNA elements with the consensus sequence 5'-TAATCTAATCA-3'. Binds to chromatin containing histone H3 acetylated at 'Lys-27' (H3K27ac) and promotes deacetylation of H3K27ac. (UniProt, Q9UBX2)

Open in Phaseline: the race on DUX4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Avidity BiosciencesAOC-1020 (Del-brax)
Antisense oligonucleotide targeting DUX4 mRNA
DUX4Phase 3Facioscapulohumeral Muscular DystrophyMay 2028
Avidity BiosciencesAOC 1020
Antisense oligonucleotide targeting DUX4 mRNA
DUX4Phase 2FSHDApr 2030

Conditions

Facioscapulohumeral Muscular Dystrophy (1) FSHD (1)

Modalities

small molecule (1), other (1)

Companies

Avidity Biosciences (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.